EXAS Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of -5.4% compared to Exact Sciences's net margin of 9.08%. Exact Sciences's return on equity of -6.77% beat Quest Diagnostics's return on equity of 12.68%.

Exact Sciences has a consensus price target of $71.86, signalling upside risk potential of 21.94%. On the other hand Quest Diagnostics has an analysts' consensus of $169.77 which suggests that it could grow by 11.01%. Given that Exact Sciences has higher upside potential than Quest Diagnostics, analysts believe Exact Sciences is more attractive than Quest Diagnostics.

Exact Sciences has a beta of 1.237, which suggesting that the stock is 23.719% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.94% to investors and pays a quarterly dividend of $0.75 per share. Exact Sciences pays -- of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exact Sciences quarterly revenues are $708.7M, which are smaller than Quest Diagnostics quarterly revenues of $2.5B. Exact Sciences's net income of -$38.2M is lower than Quest Diagnostics's net income of $226M. Notably, Exact Sciences's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 4.01x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of -5.4% compared to Exact Sciences's net margin of -56.28%. Exact Sciences's return on equity of -6.77% beat Guardant Health's return on equity of -651%.

Exact Sciences has a consensus price target of $71.86, signalling upside risk potential of 21.94%. On the other hand Guardant Health has an analysts' consensus of $42.30 which suggests that it could grow by 39.18%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

Exact Sciences has a beta of 1.237, which suggesting that the stock is 23.719% more volatile than S&P 500. In comparison Guardant Health has a beta of 1.255, suggesting its more volatile than the S&P 500 by 25.526%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $708.7M, which are larger than Guardant Health quarterly revenues of $191.5M. Exact Sciences's net income of -$38.2M is higher than Guardant Health's net income of -$107.8M. Notably, Exact Sciences's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 4.01x versus 5.45x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -5.4% compared to Exact Sciences's net margin of 65.28%. Exact Sciences's return on equity of -6.77% beat Illumina's return on equity of -37.83%.

Exact Sciences has a consensus price target of $71.86, signalling upside risk potential of 21.94%. On the other hand Illumina has an analysts' consensus of $148.36 which suggests that it could grow by 21.13%. Given that Exact Sciences has higher upside potential than Illumina, analysts believe Exact Sciences is more attractive than Illumina.

Exact Sciences has a beta of 1.237, which suggesting that the stock is 23.719% more volatile than S&P 500. In comparison Illumina has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.544%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $708.7M, which are smaller than Illumina quarterly revenues of $1.1B. Exact Sciences's net income of -$38.2M is lower than Illumina's net income of $705M. Notably, Exact Sciences's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 4.01x versus 4.89x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -5.4% compared to Exact Sciences's net margin of 3.64%. Exact Sciences's return on equity of -6.77% beat Progyny's return on equity of 11.31%.

Exact Sciences has a consensus price target of $71.86, signalling upside risk potential of 21.94%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 30.14%. Given that Progyny has higher upside potential than Exact Sciences, analysts believe Progyny is more attractive than Exact Sciences.

Exact Sciences has a beta of 1.237, which suggesting that the stock is 23.719% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $708.7M, which are larger than Progyny quarterly revenues of $286.6M. Exact Sciences's net income of -$38.2M is lower than Progyny's net income of $10.4M. Notably, Exact Sciences's price-to-earnings ratio is -- while Progyny's PE ratio is 24.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 4.01x versus 1.25x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.